This column discusses preemption defenses employed in pharmaceutical products liability cases – chief among them is the Food and Drug Administration (FDA)’s Changes Being Effected (CBE) regulations which allow brand manufacturers to modify a product label without prior FDA approval. Mintz Litigation Member Arameh O’Boyle and Associate Clancy Galgay authored the piece.

Source

American Bar Association